Hepatitis C Virus Infection and Dialysis: 2012 Update
Table 1
Recommended treatment of HCV infection in patients with chronic kidney disease.
Stage of CKD
IFN
Ribavirin
1 and 2
Pegylated IFN α-2a: 180 μg weekly by subcutaneous route Pegylated IFN α-2b: 1.5 μg/kg−1 weekly by subcutaneous route
800–1200 mg day−1 in two divided doses (by oral route)
3 and 4
Pegylated IFN α-2a: 135 μg weekly by subcutaneous route Pegylated IFN α-2b: 1.0 μg/kg−1 weekly by subcutaneous route
Stage 3: 400–800 mg day−1 in two divided doses (by oral route) 200–400 mg daily (by oral route) for eGFR <50 mL/min per 1.73 m2
5
Pegylated IFN α-2a: 135 μg weekly by subcutaneous route Pegylated IFN α-2b: 1.0 μg/kg−1 weekly by subcutaneous route
200–400 daily (by oral route)
5D
Standard IFN α-2a: 3 mU thrice weekly by subcutaneous route Standard IFN α-2b: 1 μg kg−1 weekly by subcutaneous route or Pegylated IFN α-2a: 135 μg weekly by subcutaneous route Pegylated IFN α-2b: 1 μg kg−1 weekly by subcutaneous route